Marksans Pharma Support Long Term
Marksans Pharma Ltd. engages in the research, manufacture, marketing, and sale of pharmaceutical formulations. Its product portfolio spreads over major therapeutic areas such as oncology, gastroenterology, anti-diabetic, cardiovascular, pain management, and gynecology. The company was founded by Mark Bosco Saldanha on April 16, 1992 and is headquartered in Mumbai, India.
Buy at 70. Buy more at 50, 35
Target 100 for Short Term, 500 for Long Term
Duration 5 Years
Fundamental Snippets:
Market Cap - ₹ 2,837 Cr.
Current Price - ₹ 69.6
High / Low - ₹ 97.6 / 45.0
Stock P/E - 11.3
Book Value - ₹ 21.7
Dividend Yield - 0.36 %
ROCE - 38.9 %
ROE - 31.2 %
Face Value - ₹ 1.00
Debt to equity - 0.04
Price to book value - 3.20
PEG Ratio - 0.46
Promoter holding - 48.2 %
Change in Prom Hold - 0.00 %
Working capital - ₹ 629 Cr.
WC Days - 110
EVEBITDA - 7.40
Inven TO - 1.89
Current ratio - 3.30
Quick ratio - 1.82
Enterprise Value - ₹ 2,658 Cr.
EPS - ₹ 6.15
EPS preceding year - ₹ 2.95
Buy at 70. Buy more at 50, 35
Target 100 for Short Term, 500 for Long Term
Duration 5 Years
Fundamental Snippets:
Market Cap - ₹ 2,837 Cr.
Current Price - ₹ 69.6
High / Low - ₹ 97.6 / 45.0
Stock P/E - 11.3
Book Value - ₹ 21.7
Dividend Yield - 0.36 %
ROCE - 38.9 %
ROE - 31.2 %
Face Value - ₹ 1.00
Debt to equity - 0.04
Price to book value - 3.20
PEG Ratio - 0.46
Promoter holding - 48.2 %
Change in Prom Hold - 0.00 %
Working capital - ₹ 629 Cr.
WC Days - 110
EVEBITDA - 7.40
Inven TO - 1.89
Current ratio - 3.30
Quick ratio - 1.82
Enterprise Value - ₹ 2,658 Cr.
EPS - ₹ 6.15
EPS preceding year - ₹ 2.95
Powiązane publikacje
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.